The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID)-Reference-Cited by-同舟云学术

The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID)

Published:2012-10-25 Issue:2 Volume:36 Page:140-150
ISSN:0916-9636
Container-title:Hypertension Research
language:en
Short-container-title:Hypertens Res

Author:

Yamazaki Tsutomu,Kohro Takahide,Chujo Mitsuaki,Ishigaki Masahide,Hashimoto Takafumi

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Link

http://www.nature.com/articles/hr2012154.pdf

Reference42 articles.

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 Report. JAMA 2003; 289: 2560–2572.

2. Veterans Administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension; results in patients with diastolic blood pressures averaging 115 through 129mm Hg. JAMA 1967; 202: 1028–1034.

3. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet 1997; 350: 757–764.

4. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H ; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

5. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Guidelines for the Management of Hypertension 2009. Life Science Publishing: Tokyo. 2009.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Value of the Cardio‐Ankle Vascular Index for Cardiovascular Events in Patients at Cardiovascular Risk;Journal of the American Heart Association;2021-08-17

2. The implications of blood pressure targets from the 2018 European Society of Cardiology hypertension guidelines in Asian patients: a systematic review and meta-analysis;Annals of Saudi Medicine;2020-05

3. Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study;Medicina de Familia. SEMERGEN;2020-03

4. Magnitude of Hypotension Based on Office and Ambulatory Blood Pressure Monitoring: Results From a Cohort of 5066 Treated Hypertensive Patients Aged 80 Years and Older;Journal of the American Medical Directors Association;2017-05

5. Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives;Journal of the American Society of Hypertension;2016-09